ACB
Aurora Cannabis Inc.
ACB has slightly lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over ACB overall, supported by stronger fundamentals and stronger modeled upside.
ACB Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Strong |
ACB's balance sheet is currently strong, but its revenue, profitability and cash flow are weak.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ACB PE Valuation
ACB has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
ACB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect ACB's losses to shrink, with revenue growing.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
ACB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.36 | -500% |
| Q1 2026 | -$0.91 | -2375% |
| Q4 2025 | -$0.53 | -431% |
| Q3 2025 | -$0.14 | +$0.47 |
| Q2 2025 | $0.34 | +$0.80 |
| Q1 2025 | $0.04 | +$1.18 |
| Q4 2024 | $0.16 | +$2.37 |
| Q3 2024 | -$0.61 | +$2.63 |
ACB has swung to a loss: it lost $1.36 per share over the past year, after a profit the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over ACB on earnings quality, reporting a profit while its opponent remains loss making.
ACB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $47.5M | -23% |
| Q1 2026 | $26.8M | -58% |
| Q4 2025 | $66.2M | +6.8% |
| Q3 2025 | $63.5M | +11% |
| Q2 2025 | $62M | +5.7% |
| Q1 2025 | $63.7M | +34% |
| Q4 2024 | $62M | +37% |
| Q3 2024 | $57M | +29% |
ACB's revenue is shrinking: $48M last quarter, down 23% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -70% | -112 points |
| Q1 2026 | -66% | -33 points |
| Q4 2025 | 5.1% | -37 points |
| Q3 2025 | -20% | -17 points |
| Q2 2025 | 42% | +41 points |
| Q1 2025 | -34% | -38 points |
| Q4 2024 | 42% | +69 points |
| Q3 2024 | -3% | +14 points |
ACB's operating margin was −70% last quarter, down 112 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ACB on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over ACB on profitability, with a higher operating margin.
ACB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$6.9M | -294% |
| Q1 2026 | -$3.8M | -$3.4M |
| Q4 2025 | $7.7M | -54% |
| Q3 2025 | -$32.9M | -$12.2M |
| Q2 2025 | $3.6M | +58% |
| Q1 2025 | -$438K | +$18.4M |
| Q4 2024 | $16.9M | +$22.5M |
| Q3 2024 | -$20.7M | +$4M |
ACB has burned cash in most quarters: −$36M over the past year, against −$702,335 the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over ACB on cash generation, producing positive trailing cash flow while its opponent burns cash.
ACB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7.3% | +4.2M shares |
| 1 year | +11% | +5.9M shares |
| 3 years | +74% | +26.3M shares |
| 5 years | +212% | +41.9M shares |
| Available history | +612% | +53M shares |
ACB has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
ACB hasn't bought back shares in the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ACB Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -6.1x | Net Cash |
| Q3 2025 | 0.2x | Very low |
| Q2 2025 | -1.1x | Net Cash |
| Q1 2025 | -1.6x | Net Cash |
| Q4 2024 | -1.4x | Net Cash |
| Q3 2024 | -4.5x | Net Cash |
| Q2 2024 | -5.2x | Net Cash |
| Q4 2023 | -0.2x | Net Cash |
ACB has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
ACB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.6 | Neutral |
| Stochastic | 84.8 | Overbought |
ACB's weekly RSI is 65 (neutral) and its Stochastic is 85 (overbought).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ACB PE vs Healthcare Sector
| Metric | ACB | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ACB has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ACB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.33 | 15% above |
| 20 week MA | $3.72 | 34% above |
| 50 week MA | $3.73 | 34% above |
| 100 week MA | $4.26 | 17% above |
| 200 week MA | $5.00 | 0.2% below |
ACB has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 0.2% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over ACB on trend strength, trading above more of its moving averages.
ACB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $229.2 | $88.7 | -61% |
| 2021 | $88.7 | $61.2 | -31% |
| 2022 | $61.2 | $9.27 | -85% |
| 2023 | $9.27 | $4.76 | -49% |
| 2024 | $4.76 | $4.30 | -9.7% |
| 2025 | $4.30 | $4.49 | +4.4% |
| 2026 YTD | $4.49 | $4.99 | +11% |
ACB has finished lower in five of the last six years. It's up 11% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ACB on returns for 2026, with the stronger performance.